NEWPHARMA GROUP
ActiveSummary
NEWPHARMA GROUP has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €86.3m and a net result of €138,686. Equity is growing by about 3.8% per year across the filed financial years. Its solvency ranks better than 80% of 125 sector peers (NACE 70, financial year 2026). The computed 12-month bankruptcy probability is 0.3% (very low).
Group and network
Holdings and subsidiaries
6 holdings · 7 subsidiaries in the treeHoldings 6
Source for every holding own accounts 31-03-2026
- APOTHEEK BEAUJEAN CENTRUMsubsidiaryEquity €346,449Result €132,957100%
- APOTHEEK NOORDERLAANsubsidiaryEquity €853,762Result €36,694100%
- MEGAPARA SASFRsubsidiaryEquity -€105,523Result €68,558100%
- NEWPHARMAsubsidiaryEquity €1.8mResult €3.2m100%
- Smartvalue DistributionsubsidiaryEquity €21,929Result -€28,071100%
- Z+PHARMAsubsidiaryEquity €508,048Result €57,033100%
Stated earlier (1)
An older source named these holdings; newer accounts no longer list them.
-
100%
All subsidiaries, including indirect ones 7
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
- APOTHEEK BEAUJEAN CENTRUM 100%
- APOTHEEK NOORDERLAAN 100%
- MEGAPARA SASFR 100%
NEWPHARMA 100%1 subsidiary
- ApopharmaCH 65%
- Smartvalue Distribution 100%
- Z+PHARMA 100%
According to the annual accounts to 31-03-2026 of NEWPHARMA GROUP and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.